MS in Women: How Life Stages Shape Treatment Decisions

Multiple sclerosis rarely follows a predictable clinical course, and in women, its trajectory is closely tied to hormonal and reproductive transitions. A 2026 review in CNS Drugs reframes management not as a static protocol, but as a sequence of clinical inflection points, where priorities shift from inflammation control to reproductive planning and, later, to aging-related risk.

Early Disease: Escalating Sooner, With Caution

Pediatric-onset MS remains uncommon, but incidence rises sharply after menarche. Based on accumulating data, clinicians are increasingly applying adult treatment principles earlier in the disease course.

Higher-efficacy therapies are being used sooner, with the goal of limiting long-term disability. But this comes with an unresolved tradeoff: uncertainty about long-term safety in younger patients.

Reproductive Years: Managing Risk Around Pregnancy

Pregnancy was once treated as a contraindication to therapy. Now, it’s a period that demands more deliberate planning rather than therapeutic retreat.

Clinically, pregnancy is associated with reduced inflammatory activity, but the real vulnerability emerges after delivery. The postpartum period—particularly the first six months—represents the highest risk for relapse. This risk is strongly shaped by disease activity prior to pregnancy and whether therapy was interrupted. As a result, the focus has shifted from avoiding treatment to maintaining stability across the entire peripartum window.

This is where high-efficacy therapies have changed practice. Agents like anti-CD20 monoclonal antibodies can be timed before conception to provide sustained disease suppression with limited fetal exposure. At the same time, therapies with known rebound risk, such as natalizumab or S1P modulators, require careful sequencing or transition strategies.

At the same time, several therapies, especially monoclonal antibodies, appear to have minimal transfer into breast milk. This opens the possibility of maintaining disease control while supporting breastfeeding.

Midlife: When Symptoms Blur Diagnostic Boundaries

By the time patients reach perimenopause, inflammatory activity is often less dominant, but symptom burden increases. Fatigue, sleep disruption, mood changes, and cognitive concerns may reflect MS progression, hormonal transition, or both. Multidisciplinary care is recommended to address vasomotor symptoms, sleep quality, and mental health, which can significantly improve quality of life without altering disease-directed therapy.

With menopause, relapse rates tend to decline, while disability progression becomes more apparent. Whether this reflects loss of estrogen-mediated neuroprotection or broader aging processes remains uncertain.

What is clearer is the evidence gap. Most clinical trials exclude patients over age 55, leaving clinicians without robust guidance on how therapies perform in this population. Decisions around continuing treatment become less standardized and more individualized, requiring consideration of comorbidities, infection risk, and overall disease trajectory.

Later Life: A Broader Clinical Lens

In the postmenopausal years, inflammatory activity continues to wane, but neurodegeneration and disability accumulation persist. At the same time, risks related to cardiovascular disease, osteoporosis, and malignancy rise, often intersecting with MS-related disability.

Some patients—particularly those with late-onset or progressive disease—may still benefit from ongoing treatment. Others with stable disease may consider de-escalation or discontinuation of therapy, highlighting the need for individualized risk assessment.

A Lifespan Approach to MS Care

For clinicians managing women with MS, these findings emphasize the importance of individualized care plans that evolve with the patient alongside reproductive and biological aging. The shift toward early, high-efficacy treatment offers a strategy to stabilize disease before family planning, while the nuances of menopause require careful consideration of ongoing disease-modifying treatments versus the risks of immunosenescence.

Reference:
McConville K, Bove R. Multiple Sclerosis in Women: Impact of Different Life Stages on Treatment Decisions. CNS Drugs. 2026;40(3):305-331. doi:10.1007/s40263-025-01246-9